Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAU 2025 | The case for SABR as active treatment in renal cell carcinoma

Shankar Siva • 21 Mar 2025
EAU 2025
Genitourinary Cancer Kidney Cancer

Shankar Siva, PhD, MBBS, FRANZCR, Peter MacCallum Cancer Centre, Melbourne, Australia, comments on the role of stereotactic ablative body radiotherapy (SABR), also known as stereotactic body radiation therapy (SBRT) for a 3 cm small renal mass (SRM). The non-invasive nature and excellent outcomes that are comparable to other local treatments such as partial nephrectomy make it an ideal choice. SABR can also be an attractive choice for patients with medical comorbidities. This interview took place at the 2025 European Association of Urology (EAU) Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Shankar Siva

How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Long-term results from FASTRACK II: SABR for primary kidney cancer
2:15
Long-term results from FASTRACK II: SABR for primary kidney cancer
Shankar Siva • 16 May 2026
The importance of radiation dose and quality in improving outcomes for patients with NSCLC
1:03
The importance of radiation dose and quality in improving outcomes for patients with NSCLC
Shankar Siva • 31 May 2025

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals